Related Experiment Videos
In vitro platelet abnormality in adenosine deaminase deficiency and severe combined immunodeficiency
Insights
Platelets in an infant with adenosine deaminase deficiency showed poor aggregation responses, which were corrected by adding the enzyme. This suggests a link between adenosine metabolism and platelet function in immune deficiency.
Area of Science:
- Biochemistry
- Immunology
- Hematology
Background:
- Severe combined immune deficiency (SCID) is a group of rare genetic disorders characterized by profound defects in both T-cell and B-cell immune functions.
- Adenosine deaminase (ADA) deficiency is a specific type of SCID, leading to the accumulation of toxic metabolites, particularly adenosine, affecting immune cell development and function.
Observation:
- Platelets from an infant with ADA deficiency exhibited significantly reduced adenosine diphosphate (ADP)-induced aggregation in vitro.
- This platelet aggregation defect was reversed upon in vitro addition of purified adenosine deaminase.
- Isotopic studies revealed slow clearance and persistence of exogenous adenosine in the patient's platelet-rich plasma, inhibiting ADP-induced aggregation.
Findings:
- Direct enzyme assays confirmed very low adenosine deaminase activity in the patient's plasma and platelet lysates.
- Elevated cyclic adenosine monophosphate (cAMP) levels were detected in the patient's platelets.
- The study identified deranged adenosine metabolism and elevated cAMP in platelets as potential causes for the altered ADP response.
Implications:
- The findings suggest a novel role for adenosine metabolism and its impact on platelet function in the context of severe combined immune deficiency.
- Understanding this platelet abnormality may offer insights into potential therapeutic targets beyond immune reconstitution.
- Despite in vitro platelet dysfunction, the patient showed no clinical signs of bleeding issues, highlighting a potential dissociation between laboratory findings and clinical hemostasis.
Abstract:
The platelets of an infant with severe combined immune deficiency and adenosine deaminase deficiency showed markedly diminished responses to ADP-induced aggregation in vitro. This abnormality was corrected by the addition of purified adenosine deaminase in vitro. Exogenous adenosine added to platelet-rich plasma caused markedly prolonged inhibition of ADP-induced aggregation. This was shown by isotopic studies to be due to slow clearance of adenosine and hence persistence of this nucleoside. Direct assay for adenosine deaminiase in plasma and platelet lysates of the patient confirmed the very low activity of this enzyme. Raised cAMP levels were demonstrated in his platelets. The deranged adenosine metabolism and raised cAMP in the platelets of this child with severe combined immunodeficiency may explain the altered response to ADP. Despite the in vitro platelet aggregation abnormality, the patient had no clinical evidence of impaired hemostasis.